GE HealthCare has introduced CardioVisio for Atrial Fibrillation (AFib), a digital clinical decision support tool aimed at aiding clinicians in managing patients with AFib.

AFib is a common type of cardiac arrhythmia and is considered to be a significant contributor to cardiovascular-related deaths.

The CardioVisio tool integrates and analyses data from various sources over time, offering a visual history of a patient’s heart condition and providing evidence-based insights in line with AFib guidelines.

CardioVisio aims to assist clinicians in making informed treatment decisions, resulting in precision care for AFib patients.

GE HealthCare cardiology solutions general manager Eigil Samset said: “With CardioVisio for AFib, we’re providing cardiologists with a powerful tool that streamlines clinician image interpretation and provides a view of the history of the patient’s heart as well as their healthcare journey, including previous diagnoses, prescribed medications, interventions, and comorbidities.”

The technology was unveiled at the European Society of Cardiology Congress 2023 and is commercially available in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Our Lady of the Lake Physician Group Louisiana Cardiology Associates electrophysiologist and cardiologist Dr. Kenneth Civello said: “CardioVisio for AFib incorporates algorithms that intake available relevant data as triggers for industry-published guidelines which can help ease the burden of data overload on our staff and will enable us as healthcare providers to provide timelier, personalised and evidence-based care to our patients.”